Trending

PD-1

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate

X

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

https://pharmaphorum.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug/

Henlius claims win for PD-1 drug in small cell lung cancer

Henlius claims win for PD-1 drug in small cell lung cancer

China’s Shanghai Henlius Biotech says its experimental PD-1 inhibitor serplulimab has extended survival when added to chemotherapy in

X

Henlius claims win for PD-1 drug in small cell lung cancer

https://pharmaphorum.com/news/henlius-claims-win-for-pd-1-drug-in-small-cell-lung-cancer/

Immuno-oncology latecomer GSK shows off PD-1 drug data

Immuno-oncology latecomer GSK shows off PD-1 drug data

GlaxoSmithKline has new data showing that its cancer immunotherapy dostarlimab works as a second-line treatment for women with

X

Immuno-oncology latecomer GSK shows off PD-1 drug data

https://pharmaphorum.com/news/immuno-oncology-latecomer-gsk-shows-off-pd-1-drug-data/

BMS and Nektar to pair Opdivo with natural killer cell drug

BMS and Nektar to pair Opdivo with natural killer cell drug

BMS and Nektar’s combination latest in frenzied immunotherapy field

X

BMS and Nektar to pair Opdivo with natural killer cell drug

https://pharmaphorum.com/news/bms-nektar-pair-opdivo-natural-killer-cell-drug/

Promise for combination approach to cancer

Promise for combination approach to cancer

As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.

X

Promise for combination approach to cancer

https://pharmaphorum.com/views-and-analysis/promise-combination-approach-cancer/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com